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Abstract
Aims: To compare clinical outcome of Amplatzer PFO (APFO) to Cardia PFO (CPFO) occluder. Percutaneous 
patent foramen ovale (PFO) closure prevents stroke recurrence in stroke due to paradoxical embolism.
Methods and results: The primary endpoint was a composite of stroke, TIA, or peripheral embolism at 
follow-up. The secondary endpoint was residual shunt. Outcome was compared among 934 (APFO: 712; 
CPFO: 222) patients, and in 297 propensity score-matched patients. The primary endpoint occurred in 
29 patients (0.71/100 patient-years): four (2%) with the CPFO (0.31/100 patient-years), and 25 (4%) with the 
APFO (0.89/100 patient-years) (p=0.20). Residual shunt at six months was more frequent with the CPFO 
(31% versus 9%, p<0.001). No differences in residual shunts were seen at the last available echocardio-
graphic follow-up (9±18 months): APFO 11%, CPFO 14%, p=0.22.
Conclusions: This study suggests that PFO closure with APFO or CPFO is equally effective for the preven-
tion of recurrent events. Residual shunt was more frequent at six months with CPFO, but was similar to APFO 
at later follow-up.
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Abbreviations
APFO Amplatzer PFO occluder
ASA atrial septal aneurysm
CPFO Cardia PFO occluder
CS cryptogenic stroke 
PFO patent foramen ovale
PS propensity score 
RNE recurrent neurological events
TEE transoesophageal echocardiography 
TIA transient ischaemic attack
TTE transthoracic echocardiography
Introduction
Nearly 610,000 people experience a stroke each year in the United 
States1, while the annual incidence in Europe is approximately 139 
per 100,000 inhabitants2. Patent foramen ovale (PFO) is the most 
common cardiac congenital anatomical variant present on autopsy 
and is found in up to 25% of the population3,4. In 1877 Cohnheim 
suggested an association between PFO and cryptogenic stroke 
(CS)5. Lechat et al reiterated this concept in 19886. Since then, 
numerous reports have confirmed the role of PFO in the genesis of 
paradoxical embolism7-9. The annual risk attributed to paradoxical 
embolism has been estimated at 28 per 100,000 persons with PFO10. 
Mechanical percutaneous PFO closure has been developed amongst 
other therapeutic modalities. The first percutaneous PFO closure 
was described by Bridges in 199211. Since then, it has evolved into 
a manifoldly employed therapeutic modality for patients in whom 
stroke was presumably due to a paradoxical embolism.
The risk of recurrent stroke is three times higher in patients who 
present a PFO as compared to those who do not12 and encourages pro-
phylactic treatment. Whether mechanical closure is superior to medical 
treatment is still debated, but the results of the latest randomised con-
trolled RESPECT trial suggest mechanical closure to be significantly 
superior to medical therapy in preventing recurrent stroke13. The ran-
domised controlled CLOSURE I trial failed to demonstrate superior-
ity of PFO closure plus medical therapy over best medical therapy14. 
On the other hand, propensity score-matched long-term analysis13 and 
a recent meta-analysis14 comparing PFO closure with medical therapy 
showed mechanical closure superior to medical management. The lat-
ter calculated recurrent neurological events as 0.4-0.8 events per 100 
person-years (95% CI: 0.5-1.1) for transcatheter closure versus 2.5-5.0 
events per 100 person-years (95% CI: 3.6-6.9) for medical treatment. 
Considering the limited number of studies comparing the various PFO 
occluders15-20, we aimed to compare the clinical outcomes of patients 
after implantation of either the Amplatzer PFO occluder (APFO; St. 
Jude Medical, St. Paul, MN, USA) or the Cardia Intrasept occluder 
(CPFO; Cardia Inc., Eagan, MN, USA) in a large population of unse-
lected consecutive patients.
Methods
PATIENTS, DEFINITIONS AND INITIAL WORK-UP
From January 2000 to February 2011, all consecutive patients over 
18 years of age undergoing percutaneous PFO closure with either 
APFO or CPFO in two different Swiss hospitals were prospectively 
included in the SOLUTION registry. Indications included ischae-
mic stroke, transient ischaemic attack (TIA), disabling migraine, 
decompression illness (DCI), and peripheral embolism. Stroke and 
TIA were defined according to the World Health Organization 
(WHO). Stroke was a sudden new neurological deficit lasting 
>24 hours. TIA was considered as a neurological dysfunction last-
ing <24 hours21. Neurologists of the local institutions made the dis-
tinction between complex migraine and TIA. Diagnostic criteria for 
such events were the same across the different institutions as they 
are harmonised in Switzerland according to the international guide-
lines. Both centres adhered to these diagnostic criteria.
Additional evaluation and considerations were as follows:
– Stroke and TIA were presumably related to PFO if a complete 
work-up for other possible aetiologies was negative. This work-
up included brain imaging (computed tomography or magnetic 
resonance), Doppler and colour duplex examination of the 
carotid and vertebral arteries and blood testing.
– Disabling migraine headache required confirmation by a neurol-
ogist and other causes of headache had to be excluded before the 
patient could be considered for inclusion in the registry.
– Decompression sicknesses were classified according to 
Bühlmann22.
– Peripheral embolism was considered related to PFO when other 
possible cardiac sources were excluded.
The presence of PFO was confirmed by colloid bubble contrast 
transoesophageal echocardiography (TEE) or transthoracic echocar-
diography (TTE). A PFO was considered as any shunt through a sep-
tum primum and secundum gap assessed by either TTE or TEE and 
visualisation through the interatrial crossing of aerated colloid solu-
tion injected into the antecubital or femoral vein at the end of a stren-
uous and sustained Valsalva manoeuvre. Atrial septal aneurysm 
(ASA) was diagnosed using the same imaging modalities and was 
defined as a redundant and mobile interatrial septum with a minimum 
10 to 15 mm excursion during the cardiorespiratory cycle23.
INCLUSION AND EXCLUSION CRITERIA
Inclusion criteria in the registry further required successful percuta-
neous PFO closure with one of the studied devices, a signed written 
informed consent and willingness to participate in long-term fol-
low-up. Patients intolerant to antiplatelet agents or anticoagulants 
were excluded. This study was approved by all local ethics commit-
tees and complied with the Declaration of Helsinki.
STUDY DEVICES, PROCEDURES AND TREATMENT 
ASSIGNMENT
Four devices divided into two groups were used in this study. The 
Amplatzer PFO occluder (AGA Medical Corp., Golden Valley, MN, 
USA) and three Cardia devices (Cardia Inc., Eagan, MN, USA): the 
PFO-Star, the Intrasept and the Atriasept occluders. Cardia devices 
were used in a sequential order: from 2000 to 2002 the PFO-Star was 
implanted, from 2002 until March 2008 the Intrasept occluder was 
implanted and finally from March 2008 until the end of the study 
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period the Atriasept occluder was implanted. All operators were well 
trained in PFO closure. PFO closure using APFO was exclusively 
performed under local anaesthesia and fluoroscopic guidance. PFO 
closure using CPFO was usually performed under general anaesthe-
sia with TEE and fluoroscopic guidance. TTE was performed within 
24 hours to confirm correct and stable device position. All patients 
received dual antiplatelet therapy (acetylsalicylic acid 100 mg/d and 
clopidogrel 75 mg/d) for one to six months.
The device used depended on physician preferences in each cen-
tre: all patients treated at Bern University Hospital received an 
Amplatzer PFO occluder, whereas patients treated in Lausanne 
were implanted with one of the studied Cardia devices. Device 
choice in the different institutions was solely motivated by local 
policies and preferences.
DATA COLLECTION AND FOLLOW-UP
All patients were actively followed with regard to recurrence of the 
initial clinical event that led to study inclusion or to clinical events 
attributable to PFO. Follow-up data were obtained through clinic vis-
its or phone calls. The last available follow-up was considered as 
maximum follow-up. For suspected or reported adverse events all 
relevant medical documents were retrieved from one of the above-
mentioned sources. The local event adjudication committee reviewed 
each event.
Follow-up contrast echocardiography was performed in all 
patients at one and six months. After six months, subsequent echo-
cardiographic examinations were left at the discretion of the refer-
ring cardiologist.
STUDY ENDPOINTS
The pre-specified primary endpoint was a composite of stroke, 
TIA, or peripheral embolism within the maximum follow-up 
period. In patients with multiple events, the first event was consid-
ered achievement of the study endpoint. The secondary endpoint 
was residual shunt at six months and at the latest echocardiographic 
testing assessed by contrast echocardiography. Bleeding complica-
tions were classified according to the Bleeding Academic Research 
Consortium24.
STATISTICAL ANALYSIS
Analyses were performed using SPSS software version 18.0 (SPSS 
Inc., Chicago, IL, USA). Continuous variables are expressed as 
mean ± standard deviation or median with interquartile range. 
Categorical variables are expressed as counts and percentages. For 
continuous variables Q-Q plots were computed and the Kolmogorov-
Smirnov test was employed to check for a normal distribution. We 
compared baseline characteristics between patients treated with 
APFO and CPFO using a chi-square test for categorical variables, 
an unpaired t-test for continuous variables with a normal distribu-
tion and non-parametric tests such as the Wilcoxon rank sum test 
for continuous variables with a non-Gaussian distribution. We then 
used propensity score (PS) matched analysis to account for differ-
ences in baseline characteristics. PS for receiving APFO was 
estimated using a logit model including age, gender, and pretreat-
ment variables associated with device selection in the multivariable 
model at p<0.10 as independent variables (hypercholesterolaemia, 
left ventricular ejection fraction [LVEF] and PFO with concomitant 
ASA). The multivariable model was computed (AUC=0.80, good 
discrimination) using the forward stepwise selection. Greedy 
matching in the form of nearest neighbour matching within a cali-
per of ±0.05 (corresponding in this case to a quarter of the SD of the 
PS which was 0.19) on the propensity score was employed and ran-
domly matched one patient treated with CPFO to two patients 
treated with APFO. Only patients with cerebrovascular events were 
eligible for the matching procedure and were matched according to 
event type, i.e., stroke or TIA. Univariate and multivariate analysis 
was then performed on the matched sample, the dependent variable 
being treatment status, in order to account for equity in visible 
covariates and thus an ignorable treatment assignment. As the sur-
vival functions of the matched sample did not meet the proportion-
ality assumption required to perform a Cox proportional hazard 
regression, we computed odds ratios for the endpoints. Odds ratios 
for the entire study population were derived using univariable 
binary logistic regression. Odds ratios for the matched sample were 
derived using conditional binary logistic regression. Propensity 
score matching was only used for the analysis of residual shunt at 
six months and at latest follow-up. Kaplan-Meier curves were trun-
cated at nine years.
Results
BASELINE PATIENT CHARACTERISTICS
The final sample consisted of 934 patients: 712 patients in the 
APFO group, and 222 in the CPFO group. Within the CPFO group, 
36 (16%) patients received a PFO-Star, 130 (59%) the Intrasept 
occluder, and 56 (25%) the Atriasept PFO occluder.
Patient demographics are summarised in Table 1. The overall 
934-patient population had a mean age of 51.3±4.9 years and 
a majority of men (58%, n=542). Arterial hypertension, smoking, 
and hypercholesterolaemia were present in 31% (n=285), 31% 
(n=286), and 42% (n=390), respectively. The prevalence of diabe-
tes was 4% (n=35). Nearly half of the patients presented a concomi-
tant ASA (48%, n=444). Ischaemic stroke and/or TIA accounted for 
88% (n=818) of PFO closures.
The APFO group contained more male (60% vs. 52%, p=0.03), 
hypercholesterolaemic patients (45% vs. 32%, p=0.001) with a bet-
ter LVEF (65% vs. 64%, p<0.001) and fewer ASA (39% vs. 75%, 
p<0.001) than the CPFO group. The indication for PFO closure var-
ied widely and marginal indications were more frequent in the 
CPFO group.
The 2:1 (two APFO for one CPFO patient) matching of patients 
with cerebrovascular events based on the predicted probabilities on 
the propensity score was able to segregate a total of 297 patients, of 
whom 198 belonged to the APFO and 99 to the CPFO group. No 
significant differences with regard to visible covariates remained 
after the matching procedure (Table 1). In binary logistic regres-
sion, no variable independently predicted treatment assignment.
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The multivariate model used to calculate the propensity score is 
displayed in Table 2.
IMPLANTATION AND PROCEDURE-RELATED COMPLICATIONS
There was no device malfunction. Ninety-nine percent of the proce-
dures were event-free and most were performed on an out-patient 
basis. Overall, procedure-related complications occurred in 10 cases 
(1%): six (1%) belonged to the APFO and four (2%) to the CPFO 
group (p=0.27). Complications in the APFO group were as follows: 
Table 1. Baseline patient characteristics before and after propensity score matching.
Before propensity score* matching After propensity score* matching
APFO 
(N=712)
CPFO
(N=222)
Standardised 
difference
p–value APFO 
(N=198)
CPFO
(N=99)
Standardised 
difference
p–value
Age, years±SD 51±13 51±13 0.04 0.73 53±12 53±13 –0.02 0.85
Male, n (%) 427 (60) 115 (52) 0.17 0.03 94 (48) 46 (47) 0.02 0.87
Weight, kg±SD 76±16 74±16 0.14 0.02 75±18 73±15 0.11 0.52
Height, metre±SD 1.72±0.09 1.71±0.09 0.09 0.13 1.71±0.09 1.71±0.09 0.01 0.65
BMI, m2±SD 25.6±4.4 24.9±4.5 0.16 0.61 25.4±4.9 24.6±4.7 0.13 0.42
Hypertension, n (%) 226 (32) 59 (27) 0.11 0.15 58 (29) 28 (28) 0.02 0.86
Diabetes, n (%) 31 (4) 4 (2) 0.15 0.08 5 (3) 1 (1) 0.11 0.38
Smoker, n (%) 225 (32) 61 (28) 0.09 0.25 56 (28) 29 (29) –0.02 0.86
Dyslipidaemia, n (%) 318 (45) 72 (32) 0.25 0.001 70 (35) 29 (29) 0.13 0.3
Indication 0.001 1.0
TIA, n (%) 263 (37) 83 (37) –0.01 0.96 116 (59) 58 (59) 0 1.0
Stroke, n (%) 402 (56) 65 (29) 0.57 <0.0001 82 (41) 41 (41) 0 1.0
Stroke and TIA, n (%) 0 (0) 5 (2) –0.02 0.005 0 (0) 0 (0) – –
Migraine, n (%) 1 (0) 13 (6) –0.34 <0.0001 0 (0) 0 (0) – –
DCI, n (%) 0 (0) 16 (8) –0.39 <0.0001 0 (0) 0 (0) – –
Peripheral embolism, n (%) 44 (6) 2 (1) 0.29 0.003 0 (0) 0 (0) – –
Platypnoea–orthodeoxia, n (%) 0 (0) 5 (2) –0.21 0.0005 0 (0) 0 (0) – –
Other, n (%) 2 (0) 33 (15) –0.57 <0.0001 0 (0) 0 (0) – –
LA >40 mm, n (%) 142 (20) 33 (15) 0.13 0.84 42 (21) 27 (27) –0.14 0.49
LVEF, % [IQR] 65 [65–65] 64 [60–65] 0.35 <0.001 65 [60–65] 65 [60–65] –0.04 0.27
PFO + ASA, n (%) 277 (39) 167 (75) –0.79 <0.001 154 (78) 80 (81) –0.07 0.55
*The model for propensity score computation included the following variables: age, gender, dyslipidaemia, LVEF, PFO+ASA, stroke. ASA: atrial septal 
aneurysm; DCI: decompression illness; IQR: interquartile range; kg: kilogram; LA: left atrium; LVEF: left ventricular ejection fraction; m: metre; 
PFO: patent foramen ovale; SD: standard deviation; TIA: transient ischaemic attack
Table 2. Multivariate model used for propensity score calculation.
Significance Odds ratio
95% CI
Lower limit Upper limit
Gender 0.140 1.349 0.906 2.009
Dyslipidaemia 0.003 1.922 1.254 2.945
LVEF <0.001 1.096 1.052 1.142
PFO with ASA <0.001 0.159 0.102 0.249
Age 0.429 1.006 0.991 1.022
Stroke <0.001 2.785 1.844 4.207
ASA: atrial septal aneurysm; LVEF: left ventricular ejection fraction; PFO: patent foramen 
ovale
AV fistula (n=5) and branch occlusion of the right retinal artery 
(n=1). Complications in the CPFO group were as follows: atrial 
fibrillation and transient ST elevation presumably due to a gas 
embolism (n=1), transient right leg paresis (n=1), postoperative 
minor bleeding at the puncture site (n=1), and periprocedural cath-
eter thrombosis (n=1).
Of the five (2%) complications remaining after PS matching, 
three (2%) occurred in patients treated with APFO and two (2%) in 
those treated with CPFO (p=0.89).
RESIDUAL SHUNT AT SIX-MONTH ECHOCARDIOGRAPHIC 
FOLLOW-UP
Follow-up echocardiography was available in 873 patients (93%). 
It consisted of a TEE with APFO and a TTE with CPFO. Time to 
echocardiography was 6.2 (IQR 5.2-7.2) months and did slightly 
differ between the two groups (APFO 6.3 [5.9-7.2] months vs. 
CPFO 6.1 [2.8-7.3] months, p=0.005). The difference persisted 
although less significantly in the matched sample (APFO 6.1 [5.6-
7.1] months vs. CPFO 6.0 [3.4-6.9] months, p=0.04).
At six-month follow-up, residual shunt was present in 131 
patients (14%). There was a statistically significant difference 
between both groups with 62 patients (9%) in the APFO group and 
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69 patients (31%) in the CPFO group (p<0.001). The three different 
CPFO had similar residual shunts with 31% (p<0.001) for the PFO-
Star, 32% (p<0.001) for the Intrasept and 32% (p<0.001) for the 
Atriasept.
Binary logistic regression of the complete study population 
showed that treatment with APFO (OR 0.2, 95% CI: 0.12-0.33, 
p<0.001) inferred a significant decrease in odds for PFO patency at 
six months. Furthermore, male gender (OR 1.76, 95% CI: 1.03-
2.99, p=0.04) and a PFO with concomitant ASA (OR 1.94, 95% CI: 
1.2-3.13, p<0.01) significantly increased the odds of a residual 
shunt at six-month follow-up (Figure 1).
Other variables considered in the model were age (OR 0.99, 95% 
CI: 0.97-1.01, p=0.39), body weight (per additional kg) (OR 1.01, 
95% CI: 0.99-1.03, p=0.08), LVEF (OR 0.97, 95% CI: 0.93-1.01, 
p=0.18), dyslipidaemia (OR 1.39, 95% CI: 0.87-2.2, p=0.16), and 
stroke as indication for PFO closure (OR 1.23, 95% CI: 0.78-1.94, 
p=0.38) as well as TIA and stroke (OR 0.66, 95% CI: 0.06-7.79, 
p=0.75).
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Figure 2. Kaplan-Meier estimate for survival free of recurrence or 
death in the entire cohort at nine-year follow-up. APFO: Amplatzer 
PFO occluder; CPFO: Cardia PFO occluder
In the matched population, residual shunt was detected in 
52 patients (18%). Again, the APFO group showed a significantly 
lower rate of residual shunt when compared to CPFO patients (11% 
[n=21] vs. 31% [n=31], p<0.001). Figure 2 depicts the performance 
of the APFO compared to the CPFO.
FOLLOW-UP AND CLINICAL ENDPOINTS
Follow-up was available in all patients (100%) with a mean dura-
tion of 4.4±2.7 years (range 0.5-11.5 years) and differed signifi-
cantly, being longer in CPFO patients with a mean duration of 
5.8±2.9 years when compared to APFO patients who were followed 
for a mean of 3.9±2.5 years (p<0.001).
Table 3 summarises clinical follow-up. There were no significant 
differences regarding clinical outcome. At maximal follow-up, the 
primary composite endpoint occurred in 29 patients (0.71/100 
patient-years): four (2%) in the CPFO group (0.31/100 patient-
years) and 25 (4%) in the APFO group (0.89/100 patient-years) 
(p=0.20). Overall, recurrences occurred with a median time of 
1.8 years (IQR 0.5-4.3 years). They occurred somewhat earlier in 
CPFO patients (1.5 years [IQR 0.3-7.3 years]) when compared to 
the APFO patients (2.0 years [IQR 0.5-4.3 years]) but this was not 
statistically significant (p=0.78). Figure 2 depicts the Kaplan-Meier 
Table 3. Study endpoints before and after propensity score matching. 
Before propensity score matching After propensity score matching
Overall 
(N=934)
APFO 
(n=712)
CPFO 
(n=222)
OR 
(95% CI)
p-value‡ Overall 
(N=297)
APFO 
(n=198)
CPFO 
(n=99)
OR 
(95% CI)
p-value‡
Death, n (%) 8 (1) 4 (1) 4 (2) 0.31 (0.08-1.24) 0.11
Recurrence (%) 29 (3) 25 (4) 4 (2) 1.98 (0.68-5.77) 0.2
Residual shunt at 
6 months, n (%)
131 (14) 62 (9) 69 (31) 0.22 (0.15-0.33) <0.001 52 (18) 21 (11) 31 (31) 0.24 (0.12-0.48) <0.001
Residual shunt at last 
echocardiography, n (%)
86 (9) 62 (9) 24/186 (13) 0.74 (0.44-1.23) 0.24 52 (18) 21 (11) 12/85 (14) 0.67 (0.3-1.5) 0.32
Composite endpoint, n (%) 36 (4) 28 (4) 8 (4) 1.16 (0.5-2.72) 0.83
OR: odds ratio; ORs and p-values are derived from univariable logistic regression or univariable conditional logistic regression; ‡p-values are unadjusted
0 1 2 3 4 5 6 7 8
APFO
Age
Dyslipidaemia
Stroke/TIA
Stroke
PFO with ASA
LVEF
Weight
Male gender
Odds ratio
Figure 1. Multivariate model for the prediction of residual shunt at 
six-month follow-up (entire study population). APFO: Amplatzer 
PFO occluder; ASA: atrial septal aneurysm; LVEF: left ventricular 
ejection fraction; PFO: patent foramen ovale; TIA: transient 
ischaemic attack
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curve for survival free of the primary composite endpoint. Death 
was encountered in eight patients (1% - 0.14/100 patient-years): 
four (2%) in the CPFO group (0.31/100 patient-years) and four 
(1%) in the APFO group (0.14/100 patient-years) (p=0.17). Causes 
of death were as follows: generalised cancer (two), chronic kidney 
failure (one), stroke recurrence (one), dive accident in spite of 
hyperoxaemia due to a defective oxygen valve (one), car accident 
(one), multi-organ failure caused by a septic shock (one), and death 
of unknown cause (one).
Furthermore, of the 14 patients in whom the indication for PFO 
closure was migraine, six patients (43%) reported a complete disap-
pearance of their headache, six patients (43%) reported a decrease 
in its frequency and two patients (14%) did not notice any modifi-
cation of their migraine at all.
In the overall patient population, 53% of patients (n=496, 
APFO=57% vs. CPFO=41%; p<0.001) were still on aspirin, 
100 mg/d, at maximum follow-up. In the matched sample, the 
patients still on aspirin, 100 mg/d at maximum follow-up, rep-
resented 54% (n=160; APFO=56% vs. CPFO=51%; p=0.62). 
Whether aspirin was continued or not had no significant impact on 
the clinical outcome, as 14 out of 29 (in the overall sample; p=0.58) 
and two out of six (in the matched sample; p=0.42) patients who 
achieved the primary endpoint were still taking the drug daily at 
maximum follow-up.
In the matched population, patients were followed for a mean of 
4.4±2.8 years. The follow-up duration for CPFO was significantly 
longer (6.1±2.8 years) than for APFO (3.5±2.4 years; p<0.001).
RESIDUAL SHUNT AT LONGER FOLLOW-UP
No significant differences in residual shunts were reported at the 
last available echocardiographies (9±18 months): 11% for the 
APFO group versus 14% for the CPFO group, p=0.32. The delay to 
echocardiography only changed for patients in the CPFO group, 
whereas it stayed the same for patients in the APFO group.
Discussion
The present prospective registry with medium-term clinical out-
come has the following main findings:
– Percutaneous PFO closure is safe with high success and low 
complication rates.
– Recurrent stroke, TIA or peripheral embolism has an annual inci-
dence under 1%.
– Although residual shunts were initially more frequent with CPFO 
compared to APFO, both devices were equally effective for 
medium-term recurrent event prevention.
– Similarly, no differences in echocardiographic permeability 
remained during the extended follow-up.
RECURRENT NEUROLOGICAL EVENTS (RNE) AFTER PFO 
CLOSURE
The main interest of each PFO occluder must be its propensity to 
reduce RNEs. Accordingly, the strength of our data is the high num-
ber of patients, the extended follow-up (up to 11 years), and the 
non-selection of patients, reflecting real-life daily practice. We 
demonstrated that yearly RNE recurrence rate is below 1%. This is 
in accordance with previous reported incidences in registries15,20,25 
and a randomised trial14. These results underscore that percutaneous 
PFO closure is a safe procedure with a good medium-term out-
come. Given that observational studies and meta-analyses on medi-
cal treatment report higher annual RNE rates (ranging from 3.8% to 
12%)26-29, the present study insinuates that PFO occlusion is supe-
rior to medical therapy. This is consistent with a recent PS-matched 
comparison of percutaneous PFO closure with medical treatment 
where PFO closure was indeed shown to be more effective than 
medical treatment13. Prospective randomised studies with long-
term follow-up are still missing but a longer follow-up from the 
CLOSURE I trial, and results from the RESPECT and the PC trial 
are eagerly awaited.
DEVICE COMPARISON
Both devices had a 100% procedural success rate, while in the 
CLOSURE I trial the procedural success was 90%. Device selec-
tion might have had an impact on the procedure and clinical out-
come. Thrombus formation, for example, was found more 
frequently with the STARFlex closure device used in the CLOSURE 
I trial14 than in the present study.
To date, data are scarce regarding device comparison. The het-
erogeneous inclusion and follow-up duration preclude any for-
mal conclusion14-16,18,19. Some studies have consecutively enrolled 
patients, which may lead to operator-driven device selection and 
bias18. In the present registry we aimed to compare APFO to 
CPFO in a large consecutively enrolled patient population with 
an extended clinical follow-up. No differences in procedural com-
plications were seen. We found that six-month residual shunt was 
more frequent in the CPFO group than the APFO group. However, 
these differences disappeared at longer echocardiographic follow-
up and one could therefore consider that septum healing after 
APFO implantation is quicker but similar to CPFO. Again, there 
were no outcome differences regarding stroke recurrence, TIA or 
peripheral embolism.
LIMITATIONS
The main limitation of the present study is its non-randomised 
design and comparison of the two devices used at two different cen-
tres. PS matching allowed an appropriate comparison between 
patients; however, given that the inclusion criteria were physician 
and patient-based, selection bias may have occurred.
Another main limitation is the fact that multivariable adjustment 
for the primary composite endpoint in the entire study population 
was not feasible due to a lack of statistical power. The results given 
are of univariate nature and thus likely confounded.
A further limitation is the use of TTE for follow-up in the CPFO 
group. TTE has a lower sensitivity for small residual shunts than 
TEE. The residual shunt rate difference reported in favour of the 
APFO is therefore likely to be underestimated. This may also 
explain the difference between this report and a previous one 
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comparing the same device families21. Last, we must also acknowl-
edge the lack of neuroradiological data as being another limitation 
of this article.
Impact on daily practice
Due to its invasive nature, percutaneous PFO closure has been 
debated since its inception. The current data show, however, that 
percutaneous PFO closure is safe, with high success and low 
complication rates. In daily practice, the interventional commu-
nity should keep in mind that recurrent ischaemic events are kept 
to a minimum after PFO closure with an annual incidence <1%, 
and that both Amplatzer and Cardia devices perform equally in 
preventing them.
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